Is Androgen Deprivation Therapy for Prostate Cancer Associated with Cardiovascular disease ? A Meta ‐Analysis and systematic review

ConclusionsPooled result demonstrated that ADT could significantly increase the risk of CVD and AMI, but not SCD. Various ADT modalities have different impact on cardiovascular disease risk in different level. Our meta ‐analysis also indicated that the long‐term application of ADT is not associated with increased risk of AMI and CVD. Abiraterone and enzalutamide could significantly increase the incidence of cardiac events in patients who suffered from prostate cancer.

Source: Andrology - November 18, 2019 Category: Urology & Nephrology Authors: Zhen Liang, Jun Zhu, Longlong Chen, Yawei Xu, Yongjiao Yang, Rui Hu, Wei Zhang, Yuxuan Song, Yi Lu, Ningjing Ou, Xiaoqiang Liu Tags: REVIEW ARTICLE Source Type: research